Document is current
Any future updates will be listed below
-
Authors
Allen, Steven G. https://orcid.org/0000-0002-7402-4633
Zhang, Chao
Malone, Shawn
Roy, Soumyajit
Dess, Robert T.
Jackson, William C.
Mehra, Rohit
Speers, Corey
Chinnaiyan, Arul M.
Sun, Yilun
Spratt, Daniel E.
-
Funding
Funding for this research was provided by:
U.S. Army (PC151068)
- License Information
-
More Information
Article History
Received: 21 July 2023
Accepted: 18 September 2023
First Online: 18 October 2023
Declarations
:
: SM has received honoraria from Janssen, Astellas, AstraZeneca, AMGEN, Abbvie, Knight Therapeutics, and Bayer and travel support from TerSera and Sanofi. CS has a grant from the NCI to study AR-mediated radiosensitization in breast cancer. AMC has grant funding from the Howard Hughes Medical Institute and Prostate Cancer Foundation; receives royalties from Genome Dx and Hologic; receives consulting fees from Ascentage Pharma, Lynx Dx, RAAPTA, Esanik Therapeutics, Inc, Proteovant, and Flamingo Therapeutics; and holds stock options in Tempus, Inc, Lynx Dx, RAAPTA, Esanik Therapeutics, Inc, EdenRoc, Flamingo Therapeutics, and GenePath Dx. DES received honoraria from Bayer, Blue Earth, Boston Scientific, Myovant, Novartis, and Pfizer. SGA, CZ, SR, RTD, WCJ, RM, and YS have no interests to declare.
: All animal experiments were performed with the approval of the University of Michigan Institutional Animal Care and Use Committee in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The ARRIVE guidelines 2.0 were used in reporting the results.
